Savara (NASDAQ:SVRA) PT Lowered to $9.00 at JMP Securities

Savara (NASDAQ:SVRA) had its price objective cut by JMP Securities from $10.00 to $9.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a market outperform rating on the stock.

Several other analysts have also weighed in on the company. HC Wainwright increased their price target on Savara from $6.00 to $10.00 and gave the company a buy rating in a report on Thursday, June 27th. Guggenheim increased their price objective on shares of Savara from $8.00 to $10.00 and gave the stock a buy rating in a research report on Thursday, June 27th. Oppenheimer raised their price target on Savara from $11.00 to $15.00 and gave the stock an outperform rating in a research note on Wednesday, June 26th. Finally, Evercore ISI lowered their target price on shares of Savara from $10.00 to $7.00 and set an outperform rating for the company in a research note on Thursday, May 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of Buy and an average price target of $11.17.

Savara Price Performance

Shares of NASDAQ:SVRA traded down $0.01 during mid-day trading on Tuesday, reaching $4.50. The stock had a trading volume of 28,382 shares, compared to its average volume of 1,239,134. The company has a market cap of $621.85 million, a P/E ratio of -12.19 and a beta of 1.00. Savara has a 1 year low of $3.12 and a 1 year high of $5.70. The business’s 50 day moving average price is $4.29 and its 200 day moving average price is $4.61. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Research analysts expect that Savara will post -0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Algert Global LLC raised its stake in Savara by 21.0% in the second quarter. Algert Global LLC now owns 238,807 shares of the company’s stock worth $962,000 after buying an additional 41,377 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after buying an additional 4,157,385 shares in the last quarter. Susquehanna Fundamental Investments LLC grew its position in shares of Savara by 46.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 115,831 shares of the company’s stock worth $467,000 after buying an additional 36,758 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Savara by 14.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock worth $166,000 after acquiring an additional 5,335 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its holdings in Savara by 34.5% in the second quarter. Affinity Asset Advisors LLC now owns 1,546,850 shares of the company’s stock worth $6,234,000 after purchasing an additional 396,850 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.